Dr Jesus Berdeja speaks to ecancer about the use of bispecifics and CAR T cells in South America.

South America struggles with limited access to CAR T therapies, primarily available through clinical trials, with Brazil as the sole country offering approved treatments.

Logistical and economic barriers hinder access in both the US and Europe, while only a few centres in Latin America provide these therapies.

Bispecifics may offer a more practical solution, highlighting the urgent need for more clinical trials in the region to improve drug availability.